Language: 中文  |  Eng
Home About Us Doctors List New Join Doctor Comment Contact Us
Doctor's Name District Category Gender Speciality
Full Name or SurnameHot Second Hot
Building Name Time Slot Date Fee Range Keyword Search
To
個人化標靶藥 延卵巢癌存活期
 

個人化標靶藥 延卵巢癌存活期

卵巢癌是婦科癌症頭號殺手,每年致中港澳三地逾萬名婦女喪命。澳門近日引入全球首款針對BRCA基因突變患者的個人化標靶藥,有望延長患者存活期及減少復發。

香港臨床腫瘤科專科醫生潘智文指,本港每111名婦女便有一人患卵巢癌,醫學界近年確認BRCA基因突變是致病高危因素之一;該基因本可修復受損DNA及生產抑壓腫瘤的蛋白質,倘失效便易誘發癌症,研究發現平均每五名患者便有一人出現此基因突變,有家族病史或卵巢癌患者應盡早作基因檢測。

減復發風險逾八成

澳門鏡湖醫院婦產科主任黃耀斌指大部分人對卵巢癌認知不足,曾有患者腹部腫脹如懷孕37周才求醫,切除的腫瘤大如排球,直徑達20厘米,促及早治療。

澳門腫瘤醫學會指,治療卵巢癌一般採用外科手術配合化療及電療,但晚期患者復發率高達六至七成,故引入全球首款個人化標靶治療藥物PARP抑制劑;目前有12人臨床應用。抑制劑是首款針對BRCA基因突變患者的標靶藥,配合根據不同類型患者度身訂造的個人化治療方案,有助縮細腫瘤,並減少轉移、復發及副作用。國際研究發現,抑制劑能減少復發風險達82%,並延長患者無惡化存活期中位數達6.9個至近12個月不等。

 

潘智文醫生 DR. POON CHE MUN, PATRICIA

資料來源: 晴報 26-01-2016

選文來自: 香港E-大夫/醫大夫

 

 

E大夫醫生網是香港人最喜愛的醫療網站

E-Daifu.com

The above information is not medical advice, for reference only / from : E-Daifu.com

This Site Does Not Provide Medical Advice
The contents of the articles from E-daifu Site are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on the E-daifu!This website and related information providers are not responsible for any errors in the information.

     
   Close

   Close

WhatsApp Number:5548-8918

Close

E-Daifu App